Quintis Class Action
Slater and Gordon is Investigating a class action against Quintis Limited (formerly TFS Corporation Limited) on behalf of persons that acquired QIN securities between 16 December 2016 and 9 May 2017 (inclusive).
Slater and Gordon consider that eligible shareholders may have claims against Quintis in relation to losses following the company’s ASX announcement on 10 May 2017 that:
- On 16 December 2016, Santalis Pharmaceuticals (which has been a wholly-owned subsidiary of Quintis since August 2015) and Galderma (a subsidiary of Nestle) had terminated their pre-existing licencing and supply agreement; and
- that termination had taken effect on 1 January 2017.
We are currently investigating whether, from 16 December 2016, Quintis contravened its obligations of continuous disclosure of price sensitive information under section 674 of the Corporations Act and ASX Listing rule 3.1, by failing to disclose to the market that the agreement between Santalis and Galderma had been terminated.
To register your interest and receive further information regarding the potential claim , please email firstname.lastname@example.org noting ‘Quintis Class Action’ in the subject line, and including your contact details.